Evidence map›Paper›PMID 41785669›Full record

Trial reportESMO open2026

Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma.

A D Colevas, V Chin, J J Park, D Adkins, M Phan, B Fang, F Forget, J Amorim, K Misiukiewicz, D Alpuim Costa and 10 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

A D ColevasStanford Cancer Center, Stanford, USA. Electronic address: colevas@stanford.edu.
V ChinSt Vincent's Health, Sydney, Australia.
J J ParkMacquarie Medical School, Macquarie University, Sydney, Australia.
D AdkinsWashington University School of Medicine, St. Louis, USA.
M PhanStephenson Cancer Center, Oklahoma City, USA.
B FangAstera Cancer Care, East Brunswick, USA.
F ForgetCentre Hospitalizer De L'Ardenne, Libramont-Chevigny, Belgium.
J AmorimHospital de Braga, Braga, Portugal.
K MisiukiewiczMount Sinai Health System, New York City, USA.
D Alpuim CostaCUF Descobertas Hospital, Lisbon, Portugal.
N RaineyCairns Hospital, Cairns, Australia.
C EvenGustave Roussy, Villejuif, France.
D J WongDepartment of Medicine, University of California Los Angeles, Los Angeles, USA.
K KerriganHuntsman Cancer Institute, Salt Lake City, USA.
Y ZhangGilead Sciences, Inc, Foster City, USA.
M DongGilead Sciences, Inc, Foster City, USA.
R RongGilead Sciences, Inc, Foster City, USA.
K CaldwellGilead Sciences, Inc, Foster City, USA.
C LeungGilead Sciences, Inc, Foster City, USA.
J DinisInstituto Português De Oncologia Do Porto Francisco Gentil, EPE, Porto, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe phase II ELEVATE HNSCC study evaluated magrolimab combinations in metastatic head and neck squamous-cell carcinoma (mHNSCC). PATIENTS AND

methodsEligible patients had previously untreated recurrent/mHNSCC (untreated cohort) or pretreated advanced/mHNSCC (pretreated cohort). Safety run-in (SRI) evaluations were followed by phase II assessments. In the SRI, the untreated cohort received magrolimab (M), pembrolizumab (Pem), and platinum/5-fluorouracil (PF) chemotherapy (MPemPF). In phase II, this cohort was randomized to MPemPF, PemPF, or M plus zimberelimab (Zim) and PF (MZimPF). The pretreated cohort received magrolimab plus docetaxel (MDtx; SRI and phase II). SRI primary endpoints were dose-limiting toxicities (DLTs) and adverse events (AEs). Phase II primary endpoints were progression-free survival (PFS; untreated recurrent/mHNSCC) and objective response rate (ORR; pretreated advanced/mHNSCC).

resultsNo DLTs occurred in the SRIs. In phase II, median PFS in the untreated cohort was 5.5 months with MPemPF (52 patients) versus 5.6 months with PemPF (54 patients; hazard ratio 1.314, 95% confidence interval 0.809-2.136). ORR was 12.2% in the pretreated cohort (41 patients). Grade 3-4 AE rates were 88.5% (MPemPF), 71.7% (PemPF), and 85.4% (MDtx). Across cohorts, 12 fatal AEs occurred (none magrolimab-related).

conclusionsThere was no benefit observed with magrolimab treatment. The study closed prematurely, limiting interpretation.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckAdultAgedDocetaxelFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedDocetaxelpembrolizumabdocetaxelmagrolimabmetastatic head and neck squamous-cell carcinomapembrolizumabzimberelimab

Identifiers

PMID41785669
PMCPMC12972991

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.